Lv1
60 积分 2024-12-10 加入
First-Line Zongertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
1天前
已完结
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
1天前
已完结
Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non-Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical Trials
1天前
已关闭
Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
1天前
已完结
Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer
1天前
已完结
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
16天前
已完结
Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and very high PD-L1 expression
16天前
已完结
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate
16天前
已完结
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
24天前
已完结
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis
26天前
已完结
皖公网安备34019202002308
